Retatrutide (LY3437943), 99.4% purity peptide

Retatrutide (LY3437943), 99.4% purity peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)

39

99.42%

C₂₂₁H₃₄₂N₄₆O₆₈

4731.33

2381089-83-2

485663353

Synthetic

Powder

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide derived from a GIP backbone, featuring non-coded residues (Aib2, Aib20, aMeL13) and a C20 fatty diacid conjugation for stability and albumin binding. It acts as a balanced agonist at glucagon (GCGR) and glucagon-like peptide-1 (GLP-1R) receptors, with enhanced potency at the glucose-dependent insulinotropic polypeptide receptor (GIPR) in in vitro assays. This molecule modulates key metabolic pathways by regulating energy expenditure, nutrient metabolism, and metabolite profiles (e.g., amino acids, lipids) through coordinated activation of its three target receptors, supported by consistent activity in cellular and animal models.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• 1. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.
• 2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial [published online ahead of print, 2023 Jun 26]. N Engl J Med. 2023;10.1056/NEJMoa2301972.
• 3. Sanyal, Arun J et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature medicine vol. 30,7 (2024): 2037-2048. doi:10.1038/s41591-024-03018-2
• 4. Ma, Jun et al. “Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.” Endocrine, 10.1007/s12020-024-03998-8. 30 Aug. 2024, doi:10.1007/s12020-024-03998-8
• 5. Ullah MI, Tamanna S. Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies. Medicines (Basel). 2025 Jul 28;12(3):19. doi: 10.3390/medicines12030019. PMID: 40843857; PMCID: PMC12372088.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.